NNP
BMRN icon

Nachman Norwood & Parrott’s BioMarin Pharmaceuticals BMRN Stock Holding History

Nachman Norwood & Parrott’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-121
Closed -$9K – 353
2020
Q3 		$9K Buy
+121
New +$12.2K ﹤0.01% 769

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Nachman Norwood & Parrott's BMRN Position: Q4 2020 in Review

Nachman Norwood & Parrott sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2020, closing a stake of 121 shares — an estimated $9K sold.

Nachman Norwood & Parrott first reported a position in BMRN in Q3 2020 and held it in 1 quarter. The position peaked at $9K in Q3 2020. 537 funds tracked by Wall St. Rank hold BMRN as of Q4 2020.

  • Nachman Norwood & Parrott reported no remaining BioMarin Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Nachman Norwood & Parrott sold 121 BioMarin Pharmaceuticals shares in Q4 2020, an estimated $9K.
  • Nachman Norwood & Parrott first reported a position in BioMarin Pharmaceuticals in Q3 2020 and held it in 1 quarter.
  • Nachman Norwood & Parrott's BioMarin Pharmaceuticals position peaked at $9K in Q3 2020.
  • 537 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2020.

Based on Nachman Norwood & Parrott's 13F filing for Q4 2020, filed 19 Jan 2021.